The Weekly Roundup

February 26, 2016 | Pamela Youngberg Dickson

In pharmacy, we seem to find ourselves talking about antitrust with some frequency. I speculate the industry presents some variables (reliable access to drugs, patient choice, the desire for cost containment, et. al.) that can make enforcing the law in the U.S. healthcare cartel (too strong a word?) a challenge. So, while we watchdog industry consolidation (a bit late), roll our eyes at Shkreli’s comeuppance, and scratch our heads each month trying to understand how DIR fees are even legal, here’s an interesting opinion piece specific to competition, patent expiration, and innovation in the insulin marketplace. Here are a couple other pieces we think you might like:

Continue reading →